Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Spektrum der Augenheilkunde
Erschienen in:

05.09.2017 | kommissionsbericht

Leitbild Diagnose und Therapie retinaler Venenverschlüsse

verfasst von: Martin Weger, Stefan Egger, MD

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Auszug

Retinale Venenverschlüsse stellen die zweithäufigste Netzhautgefäßerkrankung nach der diabetischen Retinopathie dar. Je nach Lokalisation des Verschlusses unterscheidet man einen Zentral‑, Hemiretinal- und Astvenenverschluss. Diese unterscheiden sich nicht nur in der Lokalisation des Verschlusses, sondern auch in der Visusprognose, Art und Prävalenz der Risikofaktoren und teils in den zur Verfügung stehenden Therapieoptionen. …
Vorheriger Artikel Effektivität und Frequenz der intravitrealen Injektionstherapie bei neovaskulärer altersabhängiger Makuladegeneration im Krankenhaus Hietzing im internationalen Vergleich
Nächster Artikel Neovascular age-related macular degeneration in Austria
Literatur
1.
Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010;117(2):313–9.CrossRefPubMedPubMedCentral
2.
Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol. 2001;131(1):61–77.CrossRefPubMed
3.
Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117(4):429–41.CrossRefPubMed
4.
Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2003;121(9):1297–302.CrossRefPubMed
5.
Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol. 2001;94(3):319–23.CrossRef
6.
Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology. 2007;114(3):520–4.CrossRefPubMed
7.
Werther W, Chu L, Holekamp N, Do DV, Rubio AG. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol. 2011;129(3):326–31.CrossRefPubMed
8.
Ho JD, Liou SW, Lin HC. Retinal vein occlusion and the risk of stroke development: a five-year follow-up study. Am J Ophthalmol. 2009;137(2):283–90.CrossRef
9.
O’Mahoney PR, Wong DT, Ray IG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008;126(5):692–9.CrossRefPubMed
10.
Stojakovic T, Scharnagl H, März W, Winkelmann BR, Boehm BO, Schmut O. Low density lipoprotein triglycerides and lipoprotein(a) are risk factors for retinal vascular occlusion. Clin Chim Acta. 2007;382(1–2):77–81.CrossRefPubMed
11.
The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114(5):545–54.CrossRef
12.
The Eye Disease Case-Control Study Group. Risk factors for branch vein occlusion. Am J Ophthalmol. 1993;116(3):286–96.CrossRef
13.
Hayreh SS, Zimmermann MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with central and hemiretinal vein occlusion. Ophthalmology. 2004;111(1):133–41.CrossRefPubMed
14.
Kimmel AS, McCarthy MJ, Blodi CF, Folk JC. Branch retinal vein occlusion in sarcoidosis. Am J Ophthalmol. 1989;107(5):561–2.CrossRefPubMed
15.
Lobes LA Jr, Folk JC. Syphilitic phlebitis simulating branch vein occlusion. Ann Ophthalmol. 1981;13(7):825–7.PubMed
16.
The Central Vein Occlusion Study Group.. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115(4):486–91.CrossRef
17.
Kieselbach G, Bolz M, Egger S, et al. Consensus Statement. Retinaler Venenverschluss (RVV). Diagnostik und Therapie. Österreichische Ärztezeitung 2012; Supplementum Februar:1–11.
18.
The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271–82.CrossRef
19.
Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol. 1974;78(2):OP178–92.PubMed
20.
Michels RG, Gass JD. The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol. 1974;87(2):OP166–77.
21.
Hayreh SS, Zimmerman MB. Hemicentral retinal vein occlusion: natural history of visual outcome. Retina. 2012;32(1):68–76.CrossRefPubMed
22.
Funk M, Kreichbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009;50(3):1025–32.CrossRefPubMed
23.
Lim JW. Intravitreal bevacizumab and cytokine levels in major and macular branch vein occlusion. Ophthalmologica. 2011;225(3):150–4.CrossRefPubMed
24.
Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012;90(2):e98–103.CrossRefPubMed
25.
Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102–12.CrossRefPubMed
26.
Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion:12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594–602.CrossRefPubMed
27.
Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124–33.CrossRefPubMed
28.
Campochiaro PA, Brown DA, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041–9.CrossRefPubMed
29.
Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–9.CrossRefPubMed
30.
Campochiaro PA, Raafay S, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab. The RETAIN Study. Ophthalmology. 2014;121(1):209–19.CrossRefPubMed
31.
Campochiaro PA, Wykoff C, Singer M, et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusions. Ophthalmology. 2014;121(12):2432–42.CrossRefPubMed
32.
Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93(4):452–6.CrossRefPubMed
33.
Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment of macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina. 2009;29(10):1396–403.CrossRefPubMed
34.
Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment of macular edema secondary to central retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina. 2010;30(7):1002–11.CrossRefPubMed
35.
Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92(3):351–5.CrossRefPubMed
36.
Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27(8):1004–12.CrossRefPubMed
37.
Wroblewski JJ, Wells JA 3rd, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009;127(4):374–80.CrossRefPubMed
38.
Wroblewski JJ, Wells JA, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol. 2010;149(1):147–54.CrossRefPubMed
39.
Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024–32.CrossRefPubMed
40.
Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6‑month results of the phase III GALILIEO study. Br J Ophthalmology. 2013;97(3):278–84.CrossRef
41.
Brown DM, Heier J, Clark L, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‑year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(10):429–37.CrossRefPubMed
42.
Heier JS, Clark L, Boyer D, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414–20.CrossRefPubMed
43.
Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the Phase 3 Galileo Study. Ophthalmology. 2014;121(1):202–8.CrossRefPubMed
44.
Ogura Y, Roider J, Korobelnik JF, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014;158(5):1032–8.CrossRefPubMed
45.
Campochiaro PA, Clark L, Boyer D, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538–44.CrossRefPubMed
46.
Clark WL, Boyer DS, Heier J, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-weeks results of the VIBRANT study. Ophthalmology. 2016;123(2):330–6.CrossRefPubMed
47.
Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLOS ONE. 2009;4(12):e8158.CrossRefPubMedPubMedCentral
48.
Nehme A, Edelman J. Dexamethasone inhibits high glucose‑, TNF-alpha-, and IL-1 beta induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci. 2008;49(5):2030–8.CrossRefPubMed
49.
McAllister IL, Vijaysekaran S, Chen SD, Yu DY. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol. 2009;147(5):838–46.CrossRefPubMed
50.
Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1125–8.
51.
Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101–14.CrossRefPubMedPubMedCentral
52.
Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch and central retinal vein occlusion: twelve months study results. Ophthalmology. 2011;118(12):2453–60.CrossRefPubMed
53.
54.
55.
Hoerauf H, Feltgen N, Weiss C, et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE-C): a European label study. Am J Ophthalmol. 2016;169:258–67.CrossRefPubMed
56.
57.
Narayanan R, Panchal B, Das T, et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab and ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report Nr. 1. Br J Ophthalmol. 2015;99(7):954–9.CrossRefPubMed
58.
Eadie JA, Ip MS, Kulkarni AD. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina. 2014;34(12):2439–43.CrossRefPubMed
59.
Sharareh B, et al. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethason implant in retinal vein occlusion. Retina. 2013;33(6):1227–31.CrossRefPubMed
60.
Papakostas TD, Gallemore R, Taban M, Onishi S, Wallsh J. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab and ranibizumab. Eye. 2016;30(1):79–84.CrossRefPubMed
61.
The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central retinal vein occlusion. Ophthalmology. 1995;102(10):1425–33.CrossRef
62.
The Central Vein Occlusion Study Group N report. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology. 1995;102(10):1434–44.CrossRef
63.
Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss (2012). Available from: http://​www.​dog.​org.​ Accessed: 4 Apr 2017.
Metadaten
Titel
Leitbild Diagnose und Therapie retinaler Venenverschlüsse
verfasst von
Martin Weger
Stefan Egger, MD
Publikationsdatum
05.09.2017
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 5/2017
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-017-0349-6

Weitere Artikel der Ausgabe 5/2017

Geriatric Orthoptics and Non-Paretic Diplopia in Adults

  • buchbesprechung

Erratum zu: Photorefraktive Keratektomie in Kombination mit Hornhautquervernetzung – eine Alternative zur Keratoplastik bei Keratokonus?

  • Erratum

Effektivität und Frequenz der intravitrealen Injektionstherapie bei neovaskulärer altersabhängiger Makuladegeneration im Krankenhaus Hietzing im internationalen Vergleich

  • originalarbeit

Subfoveal fluid and intraretinal edema 2 days after uneventful phacoemulsification

  • case report

Postsurgical ptosis associated with intraoperative eyelid dilatability

  • original article

Photorefraktive Keratektomie in Kombination mit Hornhautquervernetzung – eine Alternative zur Keratoplastik bei Keratokonus?

  • originalarbeit